A Phase 1-2 Study of a Farnesyltransferase Inhibitor, Tipifarnib, Combined With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

BACKGROUND: The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. METHODS: Induction consisted of idarubicin 12 mg/m(2) a day on days 1-3, c...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Jabbour, Elias, Kantarjian, Hagop, Ravandi, Farhad, Garcia-Manero, Guillermo, Estrov, Zeev, Verstovsek, Srdan, O’Brien, Susan, Faderl, Stefan, Thomas, Deborah A., Wright, John J., Cortes, Jorge
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4061136/
https://ncbi.nlm.nih.gov/pubmed/20960519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25575
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires